CUSIP 59935V107 · who reports it, how much, and how much it matters to them
12 of the 720 hedge fund managers we track reported shares of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) on Form 13F for 30 June 2026. Between them they reported USD 30m. The largest position belongs to RTW Investments, at USD 10m. The manager with the most riding on it is Lion Point Capital, where it is 5.3% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | RTW Investments2 funds on PPLI.com | USD 10m | 0.1% |
| 2 | POINT72 Asset Management17 funds on PPLI.com | USD 7.3m | 0.0% |
| 3 | Millennium Management6 funds on PPLI.com | USD 4.2m | 0.0% |
| 4 | Two Sigma Investments35 funds on PPLI.com | USD 2.7m | 0.0% |
| 5 | Marshall Wace LLP84 funds on PPLI.com | USD 2.4m | 0.0% |
| 6 | Lion Point Capital1 fund on PPLI.com | USD 1.1m | 5.3% |
| 7 | Boxer Capital Management1 fund on PPLI.com | USD 893,000 | 0.1% |
| 8 | Boothbay Fund Management2 funds on PPLI.com | USD 620,000 | 0.0% |
| 9 | Squarepoint Ops7 funds on PPLI.com | USD 311,000 | 0.0% |
| 10 | Balyasny Asset Management25 funds on PPLI.com | USD 295,000 | 0.0% |
| 11 | Citadel Advisors32 funds on PPLI.com | USD 44,069 | 0.0% |
| 12 | Bronte Capital Management Pty3 funds on PPLI.com | USD 19,283 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Lion Point Capital | USD 1.1m | 5.3% |
| 2 | RTW Investments | USD 10m | 0.1% |
| 3 | Boxer Capital Management | USD 893,000 | 0.1% |
| 4 | POINT72 Asset Management | USD 7.3m | 0.0% |
| 5 | Boothbay Fund Management | USD 620,000 | 0.0% |
| 6 | Millennium Management | USD 4.2m | 0.0% |
| 7 | Two Sigma Investments | USD 2.7m | 0.0% |
| 8 | Marshall Wace LLP | USD 2.4m | 0.0% |
| 9 | Bronte Capital Management Pty | USD 19,283 | 0.0% |
| 10 | Squarepoint Ops | USD 311,000 | 0.0% |
Milestone Pharmaceuticals Inc. trades under the symbol MIST on the Nasdaq. Its CUSIP, the code used on Form 13F, is 59935V107.
12 of the 720 hedge fund managers PPLI.com tracks reported Milestone Pharmaceuticals Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by RTW Investments (USD 10m), POINT72 Asset Management (USD 7.3m), Millennium Management (USD 4.2m), Two Sigma Investments (USD 2.7m) and Marshall Wace LLP (USD 2.4m).
12 managers in our coverage reported it, and between them they run 215 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Lion Point Capital, where the position was 5.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Milestone Pharmaceuticals Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.